ORIGINAL ARTICLE

Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations

Charles S Berenson,¹ Ragina L Kruzel,¹ Ellana Eberhardt,² Ree Dolnick,³ Hans Minderman,³ Paul K Wallace,³ Sanjay Sethi²

ABSTRACT

Additional material is

published online only. To view

please visit the journal online

(http://dx.doi.org/10.1136/

¹Infectious Disease Division,

Department of Veterans Affairs

Western New York Healthcare

New York at Buffalo School of

Medicine, Buffalo, New York,

²Pulmonary, Critical Care and

Sleep Division, Department of

New York Healthcare System,

Buffalo School of Medicine

³Department of Flow and

Cancer Institute, Buffalo,

Correspondence to

New York, USA

Buffalo, New York, USA

State University of New York at

Image Cytometry, Roswell Park

Dr Charles S Berenson, Division

of Infectious Diseases (151),

System, 3495 Bailey Avenue,

VA Western NY Healthcare

Buffalo, NY 14215, USA;

berenson@buffalo.edu

Received 1 April 2013

Published Online First

31 March 2014

Revised 24 February 2014

Accepted 27 February 2014

Veterans Affairs Western

System, State University of

USA

thoraxinl-2013-203669).

Background Alveolar macrophages (AM) in COPD have fundamentally impaired responsiveness to Toll-like receptor 2 (TLR2) and TLR4 ligands of non-typeable Haemophilus influenzae (NTHI). However, the contribution of innate immune dysfunction to exacerbations of COPD is unexplored. We hypothesised that impaired innate AM responses in COPD extend beyond NTHI to other pathogens and are linked with COPD exacerbations and severity.

Methods AMs, obtained by bronchoalveolar lavage from 88 volunteers with stable-to-moderate COPD, were incubated with respiratory pathogens (NTHI, Moraxella catarrhalis (MC), Streptococcus pneumoniae (SP) and TLR ligands lipopolysaccharide, Pam₃Cys) and elicited IL-8 and TNF- α were measured by microsphere flow cytometry. NF-kB nuclear translocation was measured by colorimetric assay. AM TLR2 and TLR4 expression was determined by immunolabeling and quantitation of mean fluorescent indices. Participants were monitored prospectively for occurrence of COPD exacerbations for 1 year following bronchoscopy. Non-parametric analyses were used to compare exacerbation-prone and nonexacerbation-prone individuals.

Results 29 subjects had at least one exacerbation in the follow-up period (exacerbation-prone) and 59 remained exacerbation-free (non-exacerbation-prone). AMs of exacerbation-prone COPD donors were more refractory to cytokine induction by NTHI (p=0.02), MC (p=0.045) and SP (p=0.046), and to TLR2 (p=0.07) and TLR4 (p=0.028) ligands, and had diminished NF- κ B nuclear activation, compared with non-exacerbationprone counterparts. AMs of exacerbation-prone subjects were more refractory to TLR2 upregulation by MC and SP (p=0.04 each).

Conclusions Our results support a paradigm of impaired innate responses of COPD AMs to respiratory pathogens, mediated by impaired TLR responses, underlying a propensity for exacerbations in COPD.

INTRODUCTION

CrossMark

To cite: Berenson CS, Kruzel RL, Eberhardt E, et al. Thorax 2014;69:811-818.

Exacerbations are major contributors to morbidity with and mortality associated

basis for this predilection remains unknown.

Approximately half of the exacerbations are driven by acquisition of new strains of respiratory bacterial pathogens, and increased risk of COPD exacerbation is associated with increased mortality.^{2 3} The individual propensity for COPD exacerbations varies widely. However, the underlying biological

Key messages

What is the key question?

Alveolar macrophage dysfunction and bacterial persistence promote progression of COPD. What is the contribution of innate immune dysfunction to the predilection for exacerbations of COPD?

What is the bottom line?

Alveolar macrophages of exacerbation-prone COPD donors were more refractory to cytokine induction by respiratory bacterial pathogens, through Toll-like receptor 2 (TLR2) and TLR4 signalling, and to microbial upregulation of TLR expression, than their non-exacerbation-prone counterparts.

Why read on?

This study supports a paradigm of impaired innate responses of COPD alveolar macrophages to respiratory pathogens, mediated by impaired TLR responses, underlying a propensity for COPD exacerbations.

We previously discovered fundamental immunological impairments of alveolar macrophages in COPD. Alveolar macrophages of adults with COPD had impaired inflammatory cytokine responsiveness to non-typeable Haemophilus influenzae (NTHI) outer membrane protein (OMP) P6, a Toll-like receptor 2 (TLR2) ligand and to lipooligosaccharide, a TLR4 ligand, suggesting impaired TLR signalling in COPD alveolar macrophages.⁴ Additionally, COPD alveolar macrophages had diminished phagocytosis of NTHI, suggesting wide-ranging intracellular signalling dysfunction.⁵ These findings support a potential role for TLR signalling in COPD-associated pathology. Interactions between human macrophages and respiratory pathogens are critical to the pathogenesis of COPD, and failure to evoke a strong proinflammatory alveolar macrophage response may permit evasion of immune clearance of respiratory pathogens, perpetuating infection.

Each bacterial species that causes infection in COPD displays unique dynamics of colonisation



COPD.



and interaction with human cells. NTHI, the most common cause of COPD exacerbations, exhibits heterogeneous patterns of colonisation with high turnover of strains interspersed with long-term persistence and induces strain-specific immunological responses.⁶ ⁷ *Moraxella catarrhalis*, the second most common cause of COPD exacerbations, has shorter periods of colonisation.⁸ ⁹ While NTHI and *M catarrhalis* are almost exclusively mucosal pathogens,⁷ ⁹ Streptococcus pneumoniae causes invasive disease and community-acquired pneumonia, as well as mucosal pathology in COPD.¹⁰ ¹¹ Each pathogen presents a unique set of potential immunological triggers for different host pathways.

Our previous investigations were limited to study of NTHI and did not determine whether defective immune responsiveness discriminated among respiratory pathogens.^{4 5} Notably, these studies did not address the link between impaired alveolar macrophage innate defence and COPD exacerbations. Immunological links with exacerbations have been described. Diminished peripheral T lymphocyte proliferative responses to NTHI OMP P6, as well as sputum IL-6 and IL-8 induction, are associated with exacerbations.¹²⁻¹⁴ Moreover, increased risk of COPD exacerbation is associated with acquisition of new respiratory strains of NTHI.¹⁵ However, the underlying immunological triggers have not been explained. We hypothesised that dysfunctional innate immune responses in COPD, specifically impaired proinflammatory cytokine and TLR induction, are associated with COPD exacerbations and performed experiments to test this hypothesis.

MATERIALS AND METHODS Subject recruitment

All procedures received VAWNY and University at Buffalo Institutional Review Board approval. After informed consent, volunteers were screened by spirometry (details provided in online supplement). Participants with stable COPD were enrolled and underwent bronchoscopy. All were followed prospectively for occurrence of exacerbations by bimonthly telephone contacts and 6-month and 12-month clinic visits. Participants experiencing at least one exacerbation requiring healthcare use over the study period were considered 'exacerbation-prone'. Those without a defined exacerbation were labelled 'non-exacerbation-prone'. Strict inclusion, exclusion and exacerbation criteria are detailed in the online supplement.

Purification of human alveolar macrophages

Ninety-six participants underwent right middle lobe bronchoalveolar lavage (BAL) to obtain alveolar macrophages.⁴ ⁵ Follow-up evaluation was done 24 h postbronchoscopy. Alveolar macrophage purification is detailed in the online supplement.

Cytokine induction

- A. Macrophage-bacteria interaction: Three distinct respiratory pathogens, obtained during COPD exacerbations, were used: NTHI 11P6H1; *S pneumoniae* 25P55S1 and *M catarrhalis* 6P29B1. Each donor's alveolar macrophages were inoculated with each strain (MOI- alveolar macrophage:bacteria= 1:200). Supernatants were harvested (3 h) for IL-8 and TNF- α analysis. Details of controls, bacterial strains and dose-response curves are provided in the online supplement.
- B. Macrophage–TLR ligand interaction: Alveolar macrophages were incubated with purified TLR2 (tripalmitoyl cysteine (Pam₃Cys); EMC Microcollections GmbH, Tuebingen, Germany) and TLR4 (*Escherichia coli* K235 lipopolysaccharide (LPS); Sigma Chemical Co.) ligands (1 μg/mL; 3 h),

to determine responses of alveolar macrophages to TLR2 and TLR4 ligands. Supernatants were harvested for IL-8 and TNF- α analysis. Dose–response and time–response curves are provided in the online supplement.

C. Cytokine analysis: IL-8 and TNF- α concentrations were determined by multianalyte microsphere flow cytometry.³ ¹⁶ Lower limits of detection were 6.2 and 3.6 pg/mL, respectively. Concentrations were corrected for inter-experiment differences in macrophage numbers.

TLR expression

- A. Immunostaining: Alveolar macrophages were adhered on chamber slides (Nunc Inc., Naperville, Illinois, USA). Following co-incubation (1 h) with each bacteria,⁵ adherent macrophages were immunostained for TLR2 and TLR4 expression, detailed in the online supplement.
- B. *Analysis*: A minimum of five representative fields (25 cells each), for each condition for each participant, were captured digitally. Images were analysed (Image-Pro Plus V.6.3, Media Cybernetics Inc., Bethesda MD). Parameters were set to exclude background fluorescence. Fluorescent intensities were determined for each alveolar macrophage; mean fluorescent intensities (MFI) of TLR2 and TLR4 expression were averaged for each participant.

NF-KB activation

Alveolar macrophages were incubated with each bacteria or buffer alone. Nuclear protein was quantitated to obtain 20 μ g nuclear protein per condition.¹⁷ Colorimetric assay for activation of NF- κ B transcription factors was performed (Active Motif, Carlsbad, California, USA), detailed in the online supplement. Results are given as fold increase from untreated macrophages.

Statistical analysis

Demographic data were normally distributed and analysed by unpaired t test for continuous variables and χ^2 test for nominal variables (table 1). Cytokine induction and TLR expression data between groups were not normally distributed and are reported as median (IQR) compared by Mann–Whitney U rank tests. Group differences were confirmed with univariate logistic regression and indicated age, FEV₁(L) and FEV₁(%predicted) to have p<1.0. Since FEV₁(L) and FEV₁(%predicted) are co-linear, only FEV₁ was used for multivariate analysis. Multivariate logistic regression models in which age and FEV₁ were added to each significant macrophage function tested were constructed to ascertain whether differences in macrophage function between exacerbators and non-exacerbators were still seen. For all comparisons, p≤0.05 was considered significant.

RESULTS

Demographics of participants

Of 96 recruited volunteers meeting inclusion criteria for bronchoscopy for this study, eight were lost to follow-up. To determine the relationship of alveolar macrophage dysfunction with COPD exacerbations, the 88 remaining participants were prospectively identified as exacerbation-prone (n=29) and non-exacerbation-prone (n=59), as detailed earlier. Age (mean years±SEM) was not significantly different between exacerbation-prone and non-exacerbation-prone COPD subjects (62.0 ± 1.7 vs 58.1 ± 1.3 ; p=0.14). Participants included 66 men and 22 women. Demographic data are presented in table 1.

Exacerbation-prone COPD subjects had significantly worse spirometric parameters (FEV_1 ; FEV_1 ,% predicted) than did non-exacerbators. Therefore, regression analyses were used to

Table 1	Demographic	characteristics	of	participants
---------	-------------	-----------------	----	--------------

÷ .	•	•	
Characteristics	Non-exacerbation- prone (n=59)	Exacerbation- prone (n=29)	p Value
Age (years), Mean±SEM	58.1±1.3	62.0±1.7	0.14
Gender, number			
Male	45	21	0.87
Female	14	8	
Race, number			
Caucasian	44	21	0.74
African–American	15	8	
Smoking status, number			
Active smokers	22	9	0.79
Ex-smokers	37	20	
Pack-years smoking, Mean±SEM	49.6±0.7	49.3±1.2	0.96
FEV ₁ (L) Mean±SEM	1.98±0.02	1.76±0.03	0.04
FEV ₁ (% predicted) Mean+SEM	64.6±0.5	57.6±0.8	0.01
FVC (L), Mean±SEM	3.52+0.1	3.38+0.7	0.52
FVC, % predicted Mean±SEM	90.0+2.5	86.6+2.9	0.42
GOLD classification*	% (n)	% (n)	0.20
1	16.9 (10)	17.2 (5)	
2	64.4 (38)	48.3 (14)	
3	18.6 (11)	34.5 (10)	

Data are expressed as mean±SEM.

*GOLD classification is as detailed in the Global Initiative for Chronic Obstructive

Lung Disease.¹⁸

determine the independent impact of group disparities in spirometric measures on immunological outcomes.

The numbers of alveolar macrophages obtained by bronchoscopy (means $\times 10^5 \pm SEM$) were 325.5 ± 84.5 for COPD exacerbators and 488.1 ± 64.1 for COPD non-exacerbators (p=0.14). No participants were taking systemic steroids or antibiotics. Fifty-four participants (59.3% of non-exacerbators; 65.5% of exacerbators) were taking bronchoactive medications, including inhaled corticosteroids in 17 (18.6% of non-exacerbators; 20.1% of exacerbators), β agonists in 52 (57.6% of nonexacerbators; 62.8% of exacerbators; 48.3% of exacerbators). For each intergroup comparison, there were no statistically significant differences in medication use.

Bacterial induction of cytokines

To determine the relative immune responsiveness of alveolar macrophages of each group to each respiratory pathogen, alveolar macrophages were incubated with NTHI, *M catarrhalis* and *S pneumoniae* and supernatants were assayed for IL-8 (figure 1) and TNF- α (figure 2). Data are expressed as median pg/mL (IQR). Baseline values (buffer-treated cells) for IL-8 were 1025 (2740) and 580 (2192) (p=0.32) and for TNF- α were 0 (22) and 0 (0.52) (p=0.36) for non-exacerbation-prone and exacerbation-prone COPD participants, respectively.

Alveolar macrophage cytokine responsiveness and COPD exacerbations

IL-8: To determine the relationship of alveolar macrophage dysfunction with COPD exacerbations, alveolar macrophages of





Figure 1 Bacterial induction of human alveolar macrophage IL-8 and COPD exacerbations. Alveolar macrophages were obtained from COPD participants who were identified prospectively over the course of the study as non-exacerbation-prone (dark grey shading) and exacerbation-prone (light grey shading). Cells were incubated with non-typeable *Haemophilus influenzae* 11P6H1 (A), *Moraxella catarrhalis* 6P29B1 (B) and *Streptococcus pneumoniae* 25P55S1 (C), and supernatant IL-8 concentrations were measured. Results are shown as box plots for each group. Each box encompasses the 25–75th IQR, with the horizontal line in each box representing median values. Each vertical bar encompasses the 10–90th centile ranges. Data correspond with the numeric values given in 'Results'. Statistical comparison of groups was performed by Mann–Whitney U rank test.

exacerbation-prone and non-exacerbation-prone participants were incubated with bacterial pathogens. Alveolar macrophages of exacerbation-prone COPD individuals were more refractory (p=0.02) to NTHI-induction of IL-8 (median pg/mL (IQR)) than were their non-exacerbation-prone counterparts (775.0 (2814) vs

Data analysis is by unpaired t test for comparison of continuous variables and by χ^2 test for comparison of nominal variables.



Figure 2 Bacterial induction of human alveolar macrophage TNF- α and COPD exacerbations. Alveolar macrophages were obtained from COPD non-exacerbation-prone (dark grey shading) and exacerbation-prone (light grey shading), incubated with non-typeable *Haemophilus influenzae* (A) and *Moraxella catarrhalis* (B), and supernatant TNF- α concentrations were measured. Results are shown as box plots for each group. Data are represented by box plots for each group, as detailed in figure 1, and correspond with the values given in 'Results'. Alveolar macrophages produced negligible concentrations of TNF- α in response to *Streptococcus pneumoniae* (not shown).

2365 (4250.5); figure 1A). Alveolar macrophage responsiveness to *M catarrhalis*-induction of IL-8 (870 (2586) vs 1710 (3383.8); p=0.045; figure 1B) and to *S pneumoniae*-induction of IL-8 (460 (1319) vs 1165 (2137.4); p=0.046; figure 1C) was also diminished among exacerbation-prone COPD participants. Thus, clear association exists between occurrence of prospectively measured COPD exacerbations and alveolar macrophage IL-8 responsiveness to respiratory bacterial triggers. Analysis of stimulated values, corrected for baseline cytokine expression, is detailed in the online supplement, further corroborating refractoriness of alveolar macrophages of exacerbation-prone participants.

TNF-α: Alveolar macrophages of exacerbation-prone COPD individuals were also more refractory (p=0.046) to NTHI-induction of TNF-α than were their non-exacerbation-prone counterparts (0 (4.3) vs 0 (19.2); figure 2A). Although differences were not statistically significant, *M catarrhalis*-induction of TNF-α was also diminished for alveolar macrophages of exacerbation-prone participants (7.0 (112.4) vs 16.1 (515.0); figure 2B) (p=0.08). *S pneumoniae* elicited only negligible TNF-α concentrations (not shown).

TLR ligand cytokine induction and COPD exacerbations

IL-8: To determine the role of alveolar macrophage TLR signalling in COPD exacerbations, alveolar macrophages of exacerbation-



Figure 3 Toll-like receptor 2 (TLR2) and TLR4 ligand induction of human alveolar macrophage IL-8. Alveolar macrophages, obtained from COPD non-exacerbation-prone (dark grey shading) and exacerbation-prone (light grey shading) participants, were incubated with the TLR4 ligand lipopolysaccharide (LPS, A) and with the TLR2 ligand tripalmitoyl cysteine (Pam₃Cys, B), and supernatant IL-8 concentration was measured. Data are represented by box plots for each group, as detailed in figure 1, and correspond with the numeric values given in 'Results'.

prone and non-exacerbation-prone participants were incubated with purified TLR2 (Pam₃Cys) and TLR4 (LPS) ligands to measure induction of IL-8. TLR4-mediated IL-8 induction of alveolar macrophages of exacerbation-prone COPD individuals was impaired (p=0.028) compared with responses of non-exacerbators (500 (1361) vs 1220 (1617); figure 3A). Although differences in TLR2-mediated IL-8 induction did not achieve statistical significance (p=0.074), results showed a trend towards diminished responses among alveolar macrophages of exacerbation-prone donors (640 (1440) vs 1160 (2179); figure 3B).

TNF- α : Alveolar macrophages of exacerbation-prone COPD individuals were also more refractory (p=0.015) to TLR4-mediated (4.7 (20.5) vs 18.8 (91.9); figure 4A) and to TLR2-mediated (21.3 (60.6) vs 53.5 (119.8)); figure 4B) induction of TNF- α (p=0.049) than were their non-exacerbation-prone counterparts.

NF-KB activation

To determine whether impaired immunological responsiveness of exacerbation-prone COPD alveolar macrophages is mediated through transcriptional regulator NF- κ B, nuclear extracts of



Figure 4 Toll-like receptor 2 (TLR2) and TLR4 ligand induction of human alveolar macrophage TNF- α . Alveolar macrophages, obtained from COPD non-exacerbation-prone (dark grey shading) and exacerbation-prone (light grey shading) participants, were incubated with lipopolysaccharide (A) and with Pam₃Cys (B), and supernatant TNF- α concentration was measured. Data are represented by box plots for each group, as detailed in figure 1, and correspond with the values given in 'Results'.

alveolar macrophages incubated with each bacteria were analysed. Comparison was made with same-donor baseline values and is expressed as the fold increase for each. Fold increase of nuclear NF- κ B for exacerbation-prone vs non-exacerbationprone COPD was 4.1 (3.5) vs 10.1 (5.9) in response to NTHI (p=0.02); 5.8 (2.5) vs 17.9 (22.0) in response to *M catarrhalis* (p=0.04) and 3.0 (5.1) vs 16.1 (16.1) in response to *S pneumoniae* (p=0.02).

TLR expression and COPD exacerbations

To determine the role of microbial regulation of alveolar macrophage TLR expression, MFIs of bacteria-induced TLR2 and TLR4 were analysed (table 2). Alveolar macrophages of active smokers exhibited excessive autofluorescence, making results difficult to interpret reliably. Therefore, analysis for these specific studies was limited to ex-smokers. Baseline MFI values (buffer-treated cells) for TLR2 were 7.4 (3.7) and 7.7 (6.0) (p=0.53) and for TLR4 were 8.9 (4.3) and 7.6 (4.4) (p=0.26) for non-exacerbation-prone and exacerbation-prone participants, respectively. However, *M catarrhalis*-induced (14.0 (6.3) vs 17.2 (4.2); figure 5, top row) and *S pneumoniae*-induced (16.1 (4.7) vs 19.8 (5.3)); figure 5, middle row) TLR2 expression was

 Table 2
 Bacterial induction of alveolar macrophage TLR2 and TLR4 expression.

	Bacterial stra	ains				
COPD groups	NTHI 11P6H1	Moraxella catarrhalis 6P29B1	Streptococcus pneumoniae 25P55S1			
TLR2 (mean fluorescent index)					
Non-exacerbation-prone	17.4 (8.6)	17.2 (4.2)	19.8 (5.3)			
Exacerbation-prone	19.1 (9.3)	14.1 (6.3)	16.1 (4.7)			
Mann–Whitney U p value	0.89	0.04	0.04			
TLR4 (mean fluorescent index)					
Non-exacerbation-prone	16.3 (5.4)	18.3 (6.9)	17.0 (5.5)			
Exacerbation-prone	18.7 (14.4)	17.8 (8.5)	14.3 (4.4)			
Mann–Whitney U p value	0.62	0.53	0.18			

Bold fonts denote statistically significant p values.

Alveolar macrophages of each donor were incubated with each bacteria and images of induced macrophage TLR expression were captured from several fields. Mean fluorescent intensities (MFIs) for TLR2 and TLR4 were measured and corrected for background expression. Each value is expressed as MFI (IQR). Non-parametric statistical comparison between groups of participants was performed. Immunostained images of one participant of each group are shown in figure 5. NTHI, non-typeable Haemophilus influenzae; TLR, Toll-like receptor.

significantly diminished in exacerbation-prone donors (p=0.04 for each). NTHI-induced TLR2 expression did not differ between the two groups (figure 5A; p=0.89). Induced TLR4 expression was no different between alveolar macrophages of exacerbation-prone and non-exacerbation-prone participants in response to all three bacterial pathogens (table 2).

To establish the relationship between bacteria-induced TLR expression and bacterial induction of IL-8, regression analyses were performed (figures 6 and 7) and confirmed by Spearman correlation. Clear association exists between NTHI-induced IL-8 and expression of both TLR2 (figure 6A; p=0.04; r=0.432) and TLR4 expression (figure 7A; p=0.05; r=0.398). *M catarrhalis*-induced IL-8 also correlated with induced TLR2 (figure 6B; p=0.0003; r=0.671) and TLR4 expression (figure 7B; p=0.007; r=0.54). *S pneumoniae*-induced IL-8 also had a strong relationship with induced TLR2 (figure 6C; p<0.001; r=0.778) and TLR4 (figure 7C; p=0.006; r=0.555) expression. Thus, strong association exists between induction of IL-8 for each bacteria and TLR expression.

Multivariate regression analyses

Because demographic group differences existed in age and FEV₁ (table 1), we created multivariate logistic regression models to determine whether intergroup differences in macrophage response were independent of demographic differences. Since cytokine induction data were not normally distributed, base 10 logarithmic values were used for the regression model. Tables with complete data (p values, ORs and 95% confidence indices) are included in the online supplement. In each of these models, macrophage IL-8 induction and TLR2 induction remained significantly different between exacerbators and non-exacerbators. All macrophage immunological responses that were significantly different as individual variables between the two groups remained so in the multivariate logistic regression, except for Pam₃Cys-induced TNF-a. Thus, demographic variables had minimal statistical effect on overall alveolar macrophage cytokine and TLR expression results.

Chronic obstructive pulmonary disease

Figure 5 Bacterial induction of human alveolar macrophage Toll-like receptor 2 (TLR2) expression. Alveolar macrophages, obtained from non-exacerbation-prone (left) and exacerbation-prone (right) COPD participants, were incubated with Moraxella catarrhalis (top row), Streptococcus pneumoniae (middle row) and non-typeable Haemophilus influenzae (bottom row), and TLR2 expression was measured. Images shown are from one participant of each group. Complete mean fluorescent intensities for all participants of each group are given in table 2.



DISCUSSION

This is the first study to demonstrate distinct correlation of alveolar macrophage dysfunction with clinical predilection towards COPD exacerbations. Furthermore, this association occurred in response to NTHI, *M catarrhalis*, and *S pneumoniae*, the three most common respiratory pathogens in COPD.¹⁹ An evoked alveolar macrophage inflammatory response is critical for innate immune-mediated bacterial clearance. Occurrence of bacterial exacerbations is primarily driven by acquisition of new bacterial pathogens in the lower respiratory tract.² Increased lower airway inflammation has been linked to increased respiratory symptoms in COPD leading to clinical exacerbations.²⁰ With the introduction of new strains of respiratory pathogens and impaired macrophage clearance, bacteria persist. Failure to clear respiratory bacteria may promote exacerbations and require adaptive immune mechanisms for pathogen clearance.

We previously discovered that alveolar macrophages of adults with COPD had impaired inflammatory cytokine responsiveness to NTHI OMP P6 and LOS, suggesting impaired signalling through TLR2 and TLR4 pathways.⁴ While TLR4 signalling plays a role in cigarette smoke-mediated inflammation, there is limited investigation into TLR-microbial interactions in COPD exacerbations.²¹ Studies in murine models support a role for TLRs in NTHI clearance from lung tissue.²² ²³ This prompted us to evaluate not only alveolar macrophage signalling though TLRs, but also microbial regulation of TLR expression in exacerbation-prone COPD individuals. The refractoriness of exacerbation-prone COPD alveolar macrophages to specific TLR2 and TLR4 ligands, by both IL-8 and TNF-α responsiveness in this study, demonstrates impaired TLR2 and TLR4 signalling among those prone to COPD exacerbations. Furthermore, diminished TLR2-mediated induction of TNF-a, as well as TLR4 induction of IL-8 and TNF-a, supports broad impairment of alveolar macrophage TLR signalling among COPD exacerbation-prone individuals, including impaired mediation of signalling through NF- κ B, a pivotal event in TLR-mediated activation of innate immune response.²⁴ The relative contributions of genetic factors and smoking to this impairment warrant further investigation. Our results suggest that determinants of TLR responsiveness provide some degree of explanation for the wide variation in exacerbation frequency.

Since colonisation with respiratory pathogens might serve as a macrophage priming mechanism, we cultured each BAL for respiratory bacteria. NTHI was retrieved from BAL of only one exacerbation-prone and two non-exacerbation-prone participants. *M catarrhalis* and *S pneumoniae* were not recovered from any samples. This likely reflects our selection criteria for individuals who were asymptomatic at the time of bronchoscopy.

Several mechanisms could mediate impaired TLR responses. The induction of TLR2 molecules on alveolar macrophages in response to M catarrhalis and S pneumoniae was associated with a propensity for exacerbations among COPD ex-smokers. Moreover, induced TLR expression was strongly associated with bacterial induction of IL-8. Collectively, these findings support a role for impaired alveolar macrophage TLR expression and signalling through bacterial cytokine induction in exacerbationprone COPD. Related studies have begun to explore induced TLR expression as a component of immune dysfunction in COPD, but have focused on sputum neutrophils and blood monocyte-derived macrophages.²⁵ ²⁶ In fact, TLR2 expression in sputum neutrophils may be subject to different regulation in COPD.²⁵ Moreover, induced TLR2 expression in alveolar macrophages was noted to be reduced among small numbers of individuals with COPD, although no correlation was sought with exacerbations in this study.²⁵ Study of TLR expression and potential regulation by bacterial products and cigarette smoke in alveolar macrophages and in COPD has been investigated.²⁶²⁷ However, the relationship of microbial regulation of alveolar



Figure 6 Bacterial induction of IL-8 and Toll-like receptor 2 (TLR2) expression. Correlation of induction of IL-8 by non-typeable *Haemophilus influenzae* (A), *Moraxella catarrhalis* (B) and *Streptococcus pneumoniae* (C) from alveolar macrophages of non-exacerbation-prone and exacerbation-prone ex-smoking COPD participants and TLR2 expression is shown. Statistical correlation was determined by regression analyses.

macrophage TLR expression to COPD exacerbations has not been previously explored. The strong association between induction of IL-8 for each bacteria and TLR expression supports a relationship, although further studies will be needed to establish an unambiguous link.



Chronic obstructive pulmonary disease

Figure 7 Bacterial induction of IL-8 and Toll-like receptor 4 (TLR4) expression. Correlation of induction of IL-8 by non-typeable *Haemophilus influenzae* (A), *Moraxella catarrhalis* (B) and *Streptococcus pneumoniae* (C) from alveolar macrophages of non-exacerbation-prone and exacerbation-prone ex-smoking COPD participants and TLR4 expression is shown. Statistical correlation was determined by regression analyses.

Exacerbations contribute substantially to morbidity and mortality in COPD.³ In fact, frequency of exacerbations is associated with shifts in proinflammatory cytokines, underscoring the importance of fundamental immune regulation.²⁸ ²⁹ Increased IL-8 in BAL fluid has been a distinguishing marker of COPD in

Chronic obstructive pulmonary disease

active smokers.³⁰ ³¹ Thus, it is intriguing that alveolar macrophages of exacerbation-prone individuals with COPD were refractory to induction of IL-8 compared with non-exacerbation-prone COPD. This suggests that alveolar macrophage IL-8 induction in exacerbation-prone COPD might be subject to a different regulation than their non-exacerbation-prone counterparts and that IL-8 in BAL fluid of COPD active smokers may be largely a product of neutrophils and epithelial cells.³²

While our results are definitive, there are inherent limitations to our study. Exacerbation frequency increases with worsening COPD, and the need for bronchoscopy limited our investigation to mild-to-moderate COPD.³³ Although the correlation of induced TLR expression for exacerbations among ex-smokers was definitive, our study of induced TLR expression does not address this immunological feature for exacerbations among COPD active smokers. Finally, while diminished IL-8 and TNF- α responsiveness of alveolar macrophages correlated with a propensity towards exacerbations, the duration and size of our study did not allow us to distinguish individuals with more frequent, from those with less frequent, exacerbations.

The present study advances our understanding of innate immune dysfunction in COPD, revealing distinct impairment of alveolar macrophages among individuals prone to exacerbations. Notably, clinical predilection towards COPD exacerbations strongly correlates with refractoriness of alveolar macrophage cytokine response to respiratory pathogens. Impaired TLR2 and TLR4 signalling and bacterial induction of TLR expression comprise an integral part of this dysfunction. Studies to address the underlying cellular mechanisms of these processes will be directed towards therapeutic strategies to improve macrophage responsiveness and reduce exacerbations in COPD. Activation of the nuclear erythroid-related factor 2 (Nrf2) pathway resulted in enhanced alveolar macrophage clearance of bacteria, suggesting a potential role in exacerbation-prone COPD.³⁴ Collectively, our findings support a dynamic immunological interaction between alveolar macrophages and respiratory pathogens as a component of predilection towards COPD exacerbations.

Acknowledgements The authors are grateful for the scientific advice offered by Timothy F Murphy. This manuscript is dedicated to the memory to our colleague, Jane Maloney, without whom this work would not have been possible.

Contributors CSB and SS provided conception and design of project, data analysis and interpretation of data. RLK did all cell biology laboratory work. EE performed acquisition of all clinical data. PKW performed multianalyte flow cytometry and cytokine data analysis. HM and RD performed fluorescent analysis.

Funding This work was supported by research grant R01HL082561-01 (CSB, SS) from the National Institutes of Health and with support from the Department of Veterans Affairs.

Competing interests None.

Patient consent Obtained.

Ethics approval VA Western New York and University at Buffalo Institutional Review Boards.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. *Lancet* 2012;379:1341–51.
- 2 Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355–65.
- 3 Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax* 2005;60:925–31.
- 4 Berenson CS, Wrona CT, Grove LJ, *et al*. Impaired alveolar macrophage response to *Haemophilus* antigens in chronic obstructive lung disease. *Am J Resp Crit Care Med* 2006;173:991–8.

- 5 Berenson CS, Garlipp MA, Grove LJ, et al. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis 2006;194:1375–84.
- 6 Murphy TF, Brauer AL, Schiffmacher AT, et al. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:266–72.
- 7 Sethi S, Wrona C, Grant BJ, et al. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:448–53.
- 8 Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. *Clin Infect Dis* 2009;49:124–31.
- 9 Murphy TF, Brauer AL, Aebi C, et al. Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease. Infect Immun 2005;73:8161–6.
- 10 Calbo E, Valdés E, Ochoa de Echagüen A, et al. Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected. Eur J Clin Microbiol Infect Dis 2009;28:971–6.
- 11 Malley R, Lipsitch M, Bogaert D, et al. Serum antipneumococcal antibodies and pneumococcal colonization in adults with chronic obstructive pulmonary disease. J Infect Dis 2007;196:928–35.
- 12 Abe Y, Murphy TF, Sethi S, et al. Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:967–71.
- 13 Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. *Thorax* 2002;57:759–64.
- 14 Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114–20.
- 15 Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465–71.
- 16 Earley M, Vogt R, Shapiro H, et al. Report from a workshop on multianalyte microsphere assays. Cytometry 2002;50:239–42.
- 17 Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265–75.
- 18 Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:532–55.
- 19 Murphy TF. The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease. *Curr Opin Infect Dis* 2006;19:225–30.
- 20 Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71–8.
- 21 Doz E, Noulin N, Boichot E, et al. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol 2008:180:1169–78.
- 22 Wieland CW, Florquin S, Maris NA, *et al*. The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable *Haemophilus influenzae* from the mouse lung. *J Immunol* 2005;175:6042–9.
- 23 Moghaddam SJ, Clement CG, De la Garza MM, et al. Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype. Am J Respir Cell Mol Biol 2008;38:629–38.
- 24 Carmody RJ, Chen YH. Nuclear factor-kappaB: activation and regulation during toll-like receptor signaling. *Cell Mol Immunol* 2007;4:31–41.
- 25 von Scheele I, Larsson K, Dahlen B, et al. Toll-like receptor expression in smokers with and without COPD. Resp Med 2010;105:1222–30.
- 26 Sarir H, Mortaz E, Karimi K, et al. Cigarette smoke regulates the expression of TLR4 and IL-8 production by human macrophages. J Inflamm 2009;6:1–9.
- 27 Droemann D, Goldmann T, Tiedje T, et al. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Resp Res 2005;6:1–8.
- 28 Wedzicha JA. Exacerbations: etiology and pathophysiologic mechanisms. *Chest* 2002;121:1365–415.
- 29 Parameswaran GI, Wrona CT, Murphy TF, et al. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis 2009;9:178.
- 30 Tanino M, Betsuyaku T, Takeyabu K, et al. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema. *Thorax* 2002;57:405–11.
- 31 Sethi S, Maloney J, Grove L, *et al*. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006;173:991–8.
- 32 Schulz C, Krätzel K, Wolf K, *et al*. Activation of bronchial epithelial cells in smokers without airway obstruction and patients with COPD. *Chest* 2004;125:1706–13.
- 33 Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128–38.
- 34 Harvey CJ, Thimmulappa RK, Sethi S, et al. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci Transl Med 2011;3:78ra32.

Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations

Charles S. Berenson, Ragina L. Kruzel, Ellana Eberhardt, Ree Dolnick, Hans Minderman, Paul K. Wallace, Sanjay Sethi

ON-LINE SUPPLEMENTAL DATA

Subject criteria

Participants were over 30 years of age. Of 96 participants with COPD, nine were lost to follow-up for monitoring of exacerbations. All participants underwent clinical assessment, routine spirometry and chest x-rays. Ex-smokers had expired breath carbon monoxide of <0.02ppm (Vitalograph Breath CO Monitor, Lenexa, KS).

For all COPD participants, exclusion criteria included a forced expiratory volume at one second (FEV₁) <35%, hypercapnia and co-morbid diseases that would render bronchoscopy unsafe. Inclusion criteria were: 1) chronic bronchitis by history and/or emphysema by chest x-ray or CT; 2) absence of other lung disease, including asthma and bronchiectasis, based on clinical evaluation; 3) chest x-ray findings that were normal or compatible with COPD, but detected no other disease; 4) FEV₁/FVC ratio below the 95% lower confidence limit of normal on spirometry; 5) non-atopic by history; 6) no antibiotic or systemic steroid use for four weeks preceding enrollment. Healthy non-smokers met all inclusion criteria of the COPD group, except #1 and #4 (above) and that all had never smoked (E1).

Exacerbation criteria

Participants were followed at six week intervals by telephone contact and by six and twelve month clinic visits, at which they were evaluated for occurrence of exacerbation in the intervening period. They were questioned about episodes of increased shortness of breath, increased sputum production or change in sputum color. Exacerbations were defined as an increase in one of more of these symptoms lasting over 24 hours, necessitating evaluation and treatment by a health care provider.

Purification of alveolar macrophages

Macrophages were cultured in RPMI1640 (BioWhittaker, Walkersville, MD) and human AB-positive serum (Nabi, Miami FL). Alveolar macrophages were purified from individual BALs and seeded onto 48 well tissue culture plates (10^5 cells/ml) in RPMI1640/10% AB-positive serum, supplemented with penicillin-streptomycin (100 U/ml) (E1). After incubation (5% CO₂, 95% humidity, 37°C) for 24 hours, non-adherent cells were removed. Remaining alveolar macrophages were consistently 98-100% esterase-positive (E1). Percent viability of alveolar macrophages (mean±SEM), by trypan blue exclusion, was 89.1 ± 1.2 , 88.7 ± 0.9 and $89.6\pm.7$ for Groups 1, 2 and 3 respectively (p>0.1).

Macrophage-bacteria incubation

Each bacterial strain was fully viable in 8% antibody-depleted serum (E2). Antibodydepleted human serum was purified by Protein G affinity chromatography (Amersham, Piscatawy, NJ) as a complement source, as previously described (E3). All three bacterial strains were obtained from sputum from COPD patients. All were associated with COPD exacerbations and all elicited a systemic and/or mucosal antibody response to the infecting strain, following the COPD exacerbations, making these strains more relevant to clinical COPD exacerbations than laboratory or type strains. All experiments included control wells treated with *E. coli* K235 LPS (1 μ g/ml) (Sigma Chemical Co., St. Louis MO) or buffer diluents of each antigen.

TLR expression

Alveolar macrophages $(2x10^5 \text{ cells/well})$ were adhered on Lab-Tek chamber slides (Nunc Inc., Naperville, IL). Macrophages were co-incubated with each bacterial strain (MOI-200:1). Anti-human-TLR2 and-TLR4 were purchased from eBiosciences, San Diego, CA. Cells were incubated with anti-human TLR2-FITC or anti-TLR4 (final concentration-1ug/ml) for one hour at 37°C in light-protected containers. After repeated rinses with PBS to remove unbound antibody, TLR4-stained cells were incubated with FITC-F(ab')₂ goat anti-mouse IgG (1:50) (Invitrogen Corp, Camarillo, CA) for 30 min at 4°C and then rinsed with PBS. Cells were kept protected from light and were analyzed by immunofluorescent image capture microscopy.

NF-κB activation

Because of limited numbers of alveolar macrophages, studies were performed with macrophages of ten non-exacerbation-prone and four exacerbation-prone donors. Alveolar macrophages were incubated with respiratory bacteria (NTHI, MC, SP at 1:200) or with buffer alone (3 hrs). Plated cells were removed from wells and centrifuged (5min at 500rpm; 4°C). Protein content of nuclear extracts was quantitated by Lowry assay to obtain 20 ug nuclear protein from 4-8 x10⁶ cells for each condition (E4). Cell pellets were resuspended in detergent-containing hypotonic buffer with centrifuged at 14000xg for 30sec (4°C). The pellet containing

nuclear extract was resuspended and incubated on a rocking platform (150rpm) in lysis buffer (30min.), before centrifugation (14000xg for 10min). Supernatant was stored at -80°C. Using reagents from manufacturer, 30ul of binding buffer followed by 20ul of nuclear extract in lysis buffer was added to each well. Control wells of buffer alone and p50 protein standards were included. Plates were sealed and incubated (one hour, room temp). After vigorous washing, 100ul of antibody to NF-κB (p50; 1:1000) was added and incubated for one hour. HRP-conjugated secondary antibody 100ul; 1:1000) was added after vigorous washing and incubated (one hr). 100ul developing solution was incubated for 1-3 min. Reactions were terminated at the appearance of color change and absorbance was read at 450nm.

REFERENCES

Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006;173:991-998.

Berenson CS, Patterson MA, Pattoli MA, et al. A monoclonal antibody to human macrophage gangliosides inhibits macrophage migration. J Leukoc Biol 1996; 59:371-379.

Yi K, Sethi S, Murphy TF. Human immune response to nontypeable Haemophilus influenzae in chronic bronchitis. J Infect Dis 1997; 176:1247-1252.

Berenson CS, Wrona CT, Grove LJ, et al. Impaired alveolar macrophage response to *Haemophilus* antigens in chronic obstructive lung disease. Am J Resp Crit Care Med 2006; 173:991-998.

Lowry OH, Rosebrough, NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. *J Biol Chem* 1951:193, 265-275.

<u>Online Supplement Table 1-Multivariate logistic regression tables</u> - Immunologic outcomes with significant association with exacerbation status were analyzed for independent association with age and FEV_1 .

IL-8 induction

Independent	Odds Ratio	95% CI	p value
Variable	1.014	0.0(0.1.0(0	0.(14
Age	1.014	0.962-1.068	0.614
FEV ₁	0.500	0.212-1.179	0.113
Log IL-8 (NTHI)	0.371	0.158-0.874	0.023
Independent	Odds Ratio	95% CI	n value
variable		507001	p varae
Age	1.025	0.972-1.080	0.363
FEV ₁	0.595	0.251-1.411	0.239
Log IL-8 (MC)	0.377	0.145-0.981	0.046
In dan an dant	Odda Datia	050/ CI	<i>a</i>
variable	Ouus Katio	93% CI	p value
Age	1.015	0.964-1.069	0.565
FEV ₁	0.464	0.196-1.098	0.081
Log IL-8 (SP)	0.435	0.190-0.997	0.049
Γ	1		1
Independent variable	Odds Ratio	95% CI	p value
Age	1.024	0.974-1.077	0.353
FEV ₁	0.533	0.227-1.251	0.148
Log IL-8	0.455	0.195-1.059	0.068
(Pam ₃ Cys)			
Independent	Odds Ratio	95% CI	p value
variable			
Age	1.025	0.975-1.078	0.337
FEV ₁	0.564	0.236-1.351	0.199
Log IL-8 (LPS)	0 400	0 170-0 842	0.036

Multivariate logistic regression tables (continued)

<u>TNF- α induction</u>

Independent	Odds Ratio	95% CI	p value
variable			
Age	1.031	0.979-1.085	0.252
FEV ₁	0.512	0.221-1.185	0.118
Log TNF-α_	0.804	0.646-1.000	0.0499
(NTHI)			
Independent variable	Odds Ratio	95% CI	p value
Age	1.030	0.980-1.083	0.241
FEV ₁	0.515	0.224-1.184	0.118
$\log \text{TNF-}\alpha$	0.851	0.694-1.045	0.123

Independent	Odds Ratio	95% CI	p value
variable			
Age	1.028	0.978-1.080	0.272
FEV ₁	0.521	0.224-1.213	0.130
Log TNF-α	0.798	0.567-1.124	0.196
(Pam ₃ Cys)			

Independent	Odds Ratio	95% CI	p value
variable			
Age	1.025	0.975-1.078	0.335
FEV ₁	0.451	0.187-1.087	0.076
Log TNF-α	0.722	0.553-0.942	0.017
(LPS)			

TLR expression

Independent	Odds Ratio	95% CI	p value
variable			
Age	1.006	0.971-1.042	0.735
FEV ₁	0.929	0.929-0.482	0.826
TLR2 (MC)	0.691	0.625-0.764	< 0.01
Independent variable	Odds Ratio	95% CI	p value
variable	0.000	0.0(0.1.004	0.000
Age	0.998	0.963-1.034	0.893
FEV ₁	0.582	0.304-1.111	0.101
TLR2 (SP)	0.770	0.711-0.833	< 0.01

<u>Online Supplement Table 2</u> - Comparison of cytokine induction results was made with measured values compared with values corrected for individual baseline cytokine values.

		Bacterial strains						
	COPD Groups	NTHI 11P6H1		M. cata 6P2	M. catarrhalis 6P29B1		S. pneumoniae 25P55S1	
		Uncorrected value	Corrected for baseline	Uncorrected value	Corrected for baseline	Uncorrected value	Corrected for baseline	
	Nonexacerbation- prone	2365 [4250.5]	993.0 [1848.3]	1710 [3383.8]	903.3 [2300.8]	1165 [2137.4]	270.5 [1246.0]	
IL-8	Exacerbation- prone	775 [2814]	321.5 [1213.6]	870 [2586]	344.8 [1514.6]	460 [1319]	13.9 [392.5]	
	Mann Whitney U p value	0.024	0.022	0.045	0.059	0.046	0.013	
	Nonexacerbation- prone	0 [19.2]	0.6 [38.9]	16.1 [515.0]	3.0 [43.9]	ND	ND	
TNF-α	Exacerbation- prone	0 [4.3]	0 [3.9]	7.0 [112.4]	0 [5.18]	ND	ND	
	Mann Whitney U p value	0.046	0.07	0.08	0.03	ND	ND	

Online Supplement Table 2 (continued)

		TLR Ligands			
	COPD Groups	LPS		Pam ₃ Cys	
		Uncorrected value	Corrected for baseline	Uncorrected value	Corrected for baseline
	Nonexacerbation-prone	1220 [1617]	341.0 [1082.6]	1160 [2179]	480.0 [1152.8]
IL-8	Exacerbation- prone	500 [1361]	33.4 [347.8]	640 [1440]	90.0 [519.0]
	Mann Whitney U p value	0.028	0.022	0.074	0.029
	Nonexacerbation-prone	18.8 [91.9]	17.1 [82.8]	53.5 [119.8]	52.7 [120.1]
TNF-α	Exacerbation- prone	4.7 [20.5]	4.5 [20.6]	21.3 [60.6]	21.3 [60.6]
	Mann Whitney U p value	0.015	0.015	0.049	0.050



Online supplement Figure 1 - Dose-response curves are shown for IL-8 induction in response to NTHI (Panel A), Pam3Cys (Panel B) and LPS (Panel C). For all experiments, n=4.



Online supplement Figure 2 - Time-response curves are shown for IL-8 induction in response to Pam3Cys (upper panel) and LPS (lower panel). For all experiments, n=4.